Skip to main content
Smart Investors Daily
TA

NASDAQ · TAK

Takeda Pharmaceutical Company Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$21.27

Up+$0.14 (+0.66%)

Updated Nov 20, 2026, 1:15 AM

SID Score

6.1/10

Composite research score

Smart Money

52/100

Neutral

Market cap
45.42B
P/E ratio
50.83
Dividend yield
3.11%
52-week range
$14.16 – $21.86
Volume
3.42M
Avg. volume
2.78M

Price performance · TAK

TAK price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

TAK closed at $21.27 after 20 trading sessions, up 4.47% for the selected period.

Last close
$21.27
Period change
+4.47%
Period low
$20.01
Period high
$21.64
Daily close
View OHLC price history
TAK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$21.39$21.615$21.235$21.273.42M
Nov 17, 2026$21.49$21.74$21.49$21.643.38M
Nov 16, 2026$21.73$21.855$21.56$21.593.26M
Nov 13, 2026$21.45$21.59$21.31$21.433.75M
Nov 12, 2026$21.20$21.34$21.075$21.123.26M
Nov 11, 2026$20.79$20.86$20.68$20.841.97M
Nov 10, 2026$20.88$20.98$20.74$20.932.95M
Nov 9, 2026$21.14$21.22$20.905$21.092.16M
Nov 6, 2026$20.62$21.085$20.57$21.022.97M
Nov 5, 2026$21.53$21.725$21.19$21.194.74M
Nov 4, 2026$20.90$21.08$20.64$21.062.98M
Nov 3, 2026$20.78$20.9076$20.705$20.752.58M
Nov 2, 2026$20.88$21.17$20.78$20.872.65M
Oct 30, 2026$21.00$21.22$20.79$20.914.62M
Oct 29, 2026$20.00$20.325$19.50$20.014.81M
Oct 28, 2026$19.78$20.235$19.78$20.153.12M
Oct 27, 2026$20.19$20.37$20.19$20.272.15M
Oct 26, 2026$20.40$20.5512$20.355$20.432.37M
Oct 23, 2026$20.28$20.39$20.17$20.242.1M
Oct 22, 2026$20.18$20.39$20.08$20.363.46M

Latest TAK news

The latest Smart Investors Daily articles mentioning TAK.

TAK research

Overview

Company profile and research snapshot.

Company profile

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TAK recent ratings
DateFirmRatingTarget
Mar 11, 2020JP MorganOverweight—
Nov 1, 2019Cowen & Co.Market Perform—
Sep 24, 2019JefferiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.